1. |
Bray F, Ren JS, Masuyer E, et al. Estimates of global cancer prevalence for 27 sites in the adult population in 2008[J]. Int J Cancer, 2013, 132(5):1133-1145.
|
2. |
Nana-Sinkam SP, Powell CA. Molecular biology of lung cancer, diagnosis and management of lung cancer, 3rd ed:American College of Chest Physicians evidence-based clinical practice guidelines[J]. Chest, 2013, 143(Suppl 5):e30S-e39S.
|
3. |
D'Addario G, Felip E, ESMO Guidelines Working Group. Nonsmall-cell lung cancer:ESMO clinical recommendations for diagnosis, treatment and follow up[J]. Ann Oncology, 2008, 19(Suppl 2):ii39-ii40.
|
4. |
Sørensen M, Pijls-Johannesma M, Felip E, et al. Small-cell lung cancer:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2010, 21(Suppl 5):v120-v125.
|
5. |
Fenton TR, Gout IT. Functions and regulation of the 70kDa ribosomal S6 kinases[J]. Int J Biochem Cell Biol, 2011, 43(1):47-59.
|
6. |
Wullschleger S, Loewith R, Hall MN. mTOR signaling in growth and metabolism[J]. Cell, 2006, 124(3):471-484.
|
7. |
Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in metaanalyses[EB/OL]. (2012-06-15)[2014-02-01]. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm.
|
8. |
庄莹, 曾波航. P-S6K1在肺癌的表达及其意义[J]. 广东医学, 2009, 30(4):517-519.
|
9. |
Dobashi Y, Suzuki S, Kimura M, et al. Paradigm of kinase-driven pa thway downstream of epidermal growth factor receptor/Akt in human lung carcinomas[J]. Hum Pathol, 2011, 42(2):214-226.
|
10. |
Dobashi Y, Suzuki S, Matsubara H, et al. Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas[J]. Cancer, 2009, 115(1):107-118.
|
11. |
Kaira K, Ohde Y, Endo M, et al. Expression of 4F2hc (CD98) in pulmonary neuroendocrine tumors[J]. Oncology, 2011, 26(4):931-937.
|
12. |
Kaira K, Oriuchi N, Takahashi T, et al. LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer[J]. Am J Transl Res, 2011, 3(5):468-478.
|
13. |
Liu D, Huang Y, Chen B, et al. Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma[J]. Cancer, 2011, 117(16):3763-3773.
|
14. |
Schmid K, Bago-Horvath Z, Berger W, et al. Dual inhibition of EGFR and mTOR pathways in small cell lung cancer[J]. Br J Cancer, 2010, 103(5):622-628.
|
15. |
Zhang Y, Ni HJ, Cheng DY. Prognostic value of phosphorylated mTOR/RPS6KB1 in non-small cell lung cancer[J]. Asian Pac J Cancer Prev, 2013, 14(6):3725-3728.
|
16. |
Filonenko VV, Tytarenko R, Azatjan SK, et al. Immunohistochemical analysis of S6K1 and S6K2 localization in human breast tumors[J]. Exp Oncol, 2004, 26(4):294-299.
|
17. |
Du W, Gerald D, Perruzzi CA, et al. Vascular tumors have increased p70 S6-kinase activation and are inhibited by topical rapamycin[J]. Lab Invest, 2013, 93(10):1115-1127.
|
18. |
Sahin F, Kannangai R, Adegbola O, et al. mTOR and P70 S6 kinase expression in primary liver neoplasms[J]. Clin Cancer Res, 2004, 10(24):8421-8425.
|
19. |
Li PD, Zhang WJ, Zhang MY, et al. Overexpression of RPS6KB1 predicts worse prognosis in primary HCC patients[J]. Med Oncol, 2012, 29(5):3070-3076.
|
20. |
侯桂琴, 刘明月, 薛乐勋, 等. 雷帕霉素对食管鳞癌细胞系EC9706的mTOR/p70S6K信号通路的影响[J]. 肿瘤, 2007, 27(3):172-175.
|
21. |
庄桂山, 张哲, 孔垂泽, 等. P70s6k和4EBP1在膀胱癌中的表达及临床意义[J]. 现代肿瘤医学, 2012, 20(12):2563-2565.
|
22. |
Ip CK, Wong AS. Exploiting p70 S6 kinase as a target for ovarian cancer[J]. Expert Opin Ther Targets, 2012, 16(6):619-630.
|
23. |
Baba HA, Wohlschlaeger J, Cicinnati VR, et al. Phosphorylation of p70S6 kinase predicts overall survival in patients with clear marginresected hepatocellular carcinoma[J]. Liver Int, 2009, 29(3):399-405.
|
24. |
Bian CX, Shi Z, Meng Q, et al. P70S6K 1 regulation of angiogenesis through VEGF and HIF-1alpha expression[J]. Biochem Biophys Res Commun, 2010, 398(3):395-399.
|
25. |
Kim EK, Kim JH, Kim HA, et al. Phosphorylated S6 kinase-1:a breast cancer marker predicting resistance to neoadjuvant chemotherapy[J]. Anticancer Res, 2013, 33(9):4073-4079.
|
26. |
Dhar R, Persaud SD, Mireles JR, et al. Proteolytic cleavage of p70 ribosomal S6 kinase by caspase-3 during DNA damage-induced apoptosis[J]. Biochemistry, 2009, 48(7):1474-1480.
|
27. |
Pearce LR, Alton GR, Richter DT, et al. Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1)[J]. Biochem J, 2010, 431(2):245-255.
|
28. |
Bussenius J, Anand NK, Blazey CM, et al. Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors[J]. Bioorg Med Chem Lett, 2012, 22(6):2283-2286.
|